吡嗪酰胺是一線抗結(jié)核藥,在肺結(jié)核的短程化療中起重要作用。但在臨床應(yīng)用過程中發(fā)現(xiàn)該藥有不良反應(yīng),可導(dǎo)致肝臟毒性,若不及時(shí)進(jìn)行保肝治療可導(dǎo)致患者死亡。目前對吡嗪酰胺肝臟毒性的作用機(jī)制尚不完全明確,因此對其所致肝臟損害的機(jī)制進(jìn)行深入研究,以減少其不良反應(yīng)則尤為重要。本文對國內(nèi)外關(guān)于吡嗪酰胺肝臟毒性的臨床報(bào)道、實(shí)驗(yàn)動(dòng)物肝臟毒性表現(xiàn)、肝臟毒性的機(jī)制研究和研究中存在的主要問題等進(jìn)行綜述。

Pyrazinamide is an important first-line drug used to treat tuberculosis that shortens the duration of tuberculosis therapy. However, hepatotoxicity has been reported during the investigation of pyrazinamide in clinical trials. Hepatotoxicity can lead fatal trouble if it is not recognized and prevented in time. However, the cellular effects of pyrazinamide and its mechanism of hepatotoxicity remain poorly understood. It is important to study the mechanism of pyrazinamide-induced hepatotoxicity and to reduce its adverse reaction. In this paper, the clinical reports about pyrazinamide-induced hepatotoxicity, experimental animal liver toxicity, study on the liver toxicity mechanism and the main problems existing in the research at home and abroad are reviewed.

國家自然科學(xué)基金(81273604);山東省科學(xué)院青年科學(xué)基金項(xiàng)目(2013QN001)